ORTX Orchard Therapeutics plc

7.91
+0.05  (+1%)
Previous Close 7.86
Open 7.9
Price To Book 2.57
Market Cap 767,815,735
Shares 97,068,993
Volume 121,581
Short Ratio
Av. Daily Volume 374,976
Stock charts supplied by TradingView

NewsSee all news

  1. Orchard Therapeutics Outlines Business Impact of COVID-19

    BOSTON and LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global leader in gene therapy, today provided an update on its business and operations, outlining how the COVID-19 pandemic

  2. Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer

    -- Mark Rothera steps down as President and CEO -- -- Frank Thomas takes on additional responsibilities as President and Chief Operating Officer -- BOSTON and LONDON, March 18, 2020 (GLOBE NEWSWIRE) -- Orchard

  3. Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020

    Commercial Preparations on Track for Potential Second Half 2020 EU Launch of OTL-200 for MLD with U.S. Regulatory Filing Expected Late 2020 / Early 2021  Initiation of Rolling U.S. Regulatory Filing for OTL-101

  4. Orchard Therapeutics to Present at Investor Conferences in March

    BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor

  5. Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results

    BOSTON and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, February

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data presented February 24, 2019.
OTL-102
X-linked chronic granulomatous disease (X-CGD)
BLA filing initially due 1H 2020 will be delayed due to COVID-19.
OTL-101
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Phase 1/2 data presented April 29, 2019.
OTL-300
Transfusion-dependent beta-thalassemia (TDBT)
BLA filing due 1H 2021.
OTL-200
Metachromatic leukodystrophy (MLD)
BLA filing due 2021.
OTL-103
Wiskott-Aldrich Syndrome (WAS)
Phase 1 additional interim data due 2H 2020.
OTL-203
MPS I
Phase 1/2 interim data due 2020.
OTL-201
MPS-IIIA

Latest News

  1. Orchard Therapeutics Outlines Business Impact of COVID-19

    BOSTON and LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global leader in gene therapy, today provided an update on its business and operations, outlining how the COVID-19 pandemic

  2. Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer

    -- Mark Rothera steps down as President and CEO -- -- Frank Thomas takes on additional responsibilities as President and Chief Operating Officer -- BOSTON and LONDON, March 18, 2020 (GLOBE NEWSWIRE) -- Orchard

  3. Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020

    Commercial Preparations on Track for Potential Second Half 2020 EU Launch of OTL-200 for MLD with U.S. Regulatory Filing Expected Late 2020 / Early 2021  Initiation of Rolling U.S. Regulatory Filing for OTL-101

  4. Orchard Therapeutics to Present at Investor Conferences in March

    BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor

  5. Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results

    BOSTON and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, February

  6. Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium

    BOSTON and LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at the 16th Annual WORLD

  7. Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors

    BOSTON and LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its board of directors. Dr.

  8. Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)

    BOSTON and LONDON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that it has received orphan drug designation from the U.S. Food and Drug

  9. Orchard Therapeutics Highlights 2020 Strategic Priorities

    Commercial Preparations on Track for Potential 2020 EU Launch of OTL-200 for Metachromatic Leukodystrophy (MLD) with U.S. Regulatory Filing Expected Late 2020 / Early 2021  Initiation of Rolling U.S. Regulatory Filing

  10. Orchard Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BOSTON and LONDON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  11. Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting

    BOSTON and LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  12. Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy

    BOSTON and LONDON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  13. European Medicines Agency Grants Orchard Therapeutics Accelerated Assessment of OTL-200 for Patients with Metachromatic Leukodystrophy

    BOSTON and LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  14. Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises

    ASH Abstracts Published Today Confirm Achievement of All Key Endpoints in Wiskott-Aldrich Syndrome Registrational Trial and Demonstrate Consistency of Data Between the Fresh and Cryopreserved Formulations of

  15. Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting

    Registrational Trial for Wiskott-Aldrich Syndrome Met Key Primary and Secondary Endpoints at Three Years; Data from Integrated Analysis Reinforce Treatment Benefits of Gene Therapy and Durability of Effect in Additional

  16. Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results

    BOSTON and LONDON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  17. Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation

    Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations Regulatory Submission in Europe

  18. Orchard Therapeutics Announces Appointment of CEO Mark Rothera to The Alliance for Regenerative Medicine's 2020 Board of Directors

    BOSTON and LONDON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  19. Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress

    BOSTON and LONDON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  20. Orchard Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  21. Orchard Therapeutics Announces Departure of Chief Commercial Officer

    BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and